Multifarious proteomic signatures and regional heterogeneity in glioblastomas

Journal of Neuro-Oncology

Volumn 94, Issue 1, 2009, Pages 31-39

  Park, Chul Kee ^a   Jung, Ji Hye ^a   Park, Sung Hye ^b   Jung, Hee Won ^a   Cho, Byung Kyu ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Glioblastoma; Heterogeneity; Mass spectrometry; Proteomics; Transthyretin; Ubiquitin carboxyl terminal esterase L1

Indexed keywords

ALPHA CRYSTALLIN; ALPHA TUBULIN; ALPHA TUBULIN 3; APOLIPOPROTEIN A1; CARBONATE DEHYDRATASE I; DIMETHYLARGININASE; DIMETHYLARGININASE 1; GLUTATHIONE TRANSFERASE; LIPOCORTIN 5; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 2; PREALBUMIN; THREONINE; TYROSINE 3 MONOOXYGENASE; UBIQUITIN THIOLESTERASE; UBIQUITIN THIOLESTERASE L1; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CASE REPORT; CONTROLLED STUDY; GENE EXPRESSION; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN ANALYSIS; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BRAIN NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM PROTEINS; PREALBUMIN; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 67650476701     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9805-8     Document Type: Article

References (53)

1. Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci USA 105:5213-5218. doi: 10.1073/pnas.0801279105
2. Earnest Ft, Kelly PJ, Scheithauer BW et al (1988) Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166:823-827
3. Hobbs SK, Shi G, Homer R et al (2003) Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 18:530-536. doi: 10.1002/jmri.10395
4. Van Meter T, Dumur C, Hafez N et al (2006) Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15:195-205. doi: 10.1097/01.pdm.0000213464.06387.36
5. Harada K, Nishizaki T, Ozaki S et al (1998) Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res 58:4694-4700
6. Loeper S, Romeike BF, Heckmann N et al (2001) Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 94:1-8. doi: 10.1159/000048773
7. Shuangshoti S, Navalitloha Y, Kasantikul V et al (2000) Genetic heterogeneity and progression in different areas within high-grade diffuse astrocytoma. Oncol Rep 7:113-117
8. Walker C, du Plessis DG, Joyce KA et al (2003) Phenotype versus genotype in gliomas displaying inter- or intratumoral histological heterogeneity. Clin Cancer Res 9:4841-4851
9. Mariani L, Beaudry C, McDonough WS et al (2001) Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin Cancer Res 7:2480-2489
10. Hoelzinger DB, Mariani L, Weis J et al (2005) Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 7:7-16. doi: 10.1593/neo.04535
11. Suzuki T, Maruno M, Wada K et al (2004) Genetic analysis of human glioblastomas using a genomic microarray system. Brain Tumor Pathol 21:27-34. doi: 10.1007/BF02482174
12. Aghi M, Gaviani P, Henson JW et al (2005) Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11:8600-8605. doi: 10.1158/ 1078-0432.CCR-05-0713
13. Necesalova E, Vranova V, Kuglik P et al (2007) Incidence of the main genetic markers in glioblastoma multiforme is independent of tumor topology. Neoplasma 54:212-218
14. Glanz C, Rebetz J, Stewenius Y et al (2007) Genetic intratumour heterogeneity in high-grade brain tumours is associated with telomere-dependent mitotic instability. Neuropathol Appl Neurobiol 33:440-454. doi: 10.1111/j.1365-2990.2007.00832.x
15. Whittle IR, Short DM, Deighton RF et al (2007) Proteomic analysis of gliomas. Br J Neurosurg 21:576-582. doi: 10.1080/02688690701721691
16. Iwadate Y, Sakaida T, Hiwasa T et al (2004) Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64:2496-2501. doi: 10.1158/0008-5472.CAN-03-1254
17. Schwartz SA, Weil RJ, Johnson MD et al (2004) Protein profiling in brain tumors using mass spectrometry: Feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 10:981-987. doi: 10.1158/ 1078-0432.CCR-0927-3
18. Odreman F, Vindigni M, Gonzales ML et al (2005) Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 4:698-708. doi: 10.1021/pr0498180
19. Furuta M, Weil RJ, Vortmeyer AO et al (2004) Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23:6806-6814. doi: 10.1038/sj.onc.1207770
20. Iwadate Y, Sakaida T, Saegusa T et al (2005) Proteome-based identification of molecular markers predicting chemosensitivity to each category of anticancer agents in human gliomas. Int J Oncol 26:993-998
21. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L et al (2006) Characterization of glioblastomas in young adults. Brain Pathol 16:273-286. doi: 10.1111/j.1750-3639.2006.00029.x
22. Chumbalkar VC, Subhashini C, Dhople VM et al (2005) Differential protein expression in human gliomas and molecular insights. Proteomics 5:1167-1177. doi: 10.1002/pmic.200401202
23. Tovi M, Hartman M, Lilja A et al (1994) MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens. Acta Radiol 35:495-505
24. Sugahara T, Korogi Y, Kochi M et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479-1486
25. Tynninen O, Aronen HJ, Ruhala M et al (1999) MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 34:427-434. doi: 10.1097/ 00004424-199906000-00007
26. Seliger B, Fedorushchenko A, Brenner W et al (2007) Ubiquitin COOH-terminal hydrolase 1: A biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 13:27-37. doi: 10.1158/1078-0432.CCR-06-0824
27. Wilkinson KD, Lee KM, Deshpande S et al (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246:670-673. doi: 10.1126/science.2530630
28. Setsuie R, Wada K (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51:105-111. doi: 10.1016/ j.neuint.2007.05.007
29. Hibi K, Liu Q, Beaudry GA et al (1998) Serial analysis of gene expression in non-small cell lung cancer. Cancer Res 58:5690-5694
30. Campbell LK, Thomas JR, Lamps LW et al (2003) Protein gene product 9.5 (PGP 9.5) is not a specific marker of neural and nerve sheath tumors: An immunohistochemical study of 95 mesenchymal neoplasms. Mod Pathol 16:963-969. doi: 10.1097/01.MP.0000087088.88280.B0
31. Hibi K, Kodera Y, Ito K et al (2004) Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinoma. Anticancer Res 24:3731-3734
32. Takano T, Miyauchi A, Matsuzuka F et al (2004) PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. Eur J Cancer 40:614-618. doi: 10.1016/j.ejca.2003.11.016
33. Sato N, Fukushima N, Maitra A et al (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63:3735-3742
34. Yamashita K, Park HL, Kim MS et al (2006) PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66:3921-3927. doi: 10.1158/ 0008-5472.CAN-05-1511
35. Lee YM, Lee JY, Kim MJ et al (2006) Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci 97:1205-1210. doi: 10.1111/ j.1349-7006.2006.00320.x
36. Yamazaki T, Hibi K, Takase T et al (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8:192-195
37. Tezel E, Hibi K, Nagasaka T et al (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6:4764-4767
38. al-Katib AM, Mohammad RM, Maki A et al (1995) Induced expression of a ubiquitin COOH-terminal hydrolase in acute lymphoblastic leukemia. Cell Growth Differ 6:211-217
39. Brichory F, Beer D, Le Naour F et al (2001) Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908-7912
40. Takase T, Hibi K, Yamazaki T et al (2003) PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 50:1278-1280
41. Otsuki T, Yata K, Takata-Tomokuni A et al (2004) Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 127:292-298. doi: 10.1111/ j.1365-2141.2004.05205.x
42. Bittencourt Rosas SL, Caballero OL, Dong SM et al (2001) Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 170:73-79. doi: 10.1016/S0304-3835(01)00449-9
43. Mandelker DL, Yamashita K, Tokumaru Y et al (2005) PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65:4963-4968. doi: 10.1158/ 0008-5472.CAN-04-3923
44. Shen H, Sikorska M, Leblanc J et al (2006) Oxidative stress regulated expression of ubiquitin carboxyl-terminal hydrolase-L1: Role in cell survival. Apoptosis 11:1049-1059. doi: 10.1007/s10495-006-6303-8
45. Ovaa H, Kessler BM, Rolen U et al (2004) Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA 101:2253-2258. doi: 10.1073/pnas.0308411100
46. Gavioli R, Frisan T, Vertuani S et al (2001) c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 3:283-288. doi: 10.1038/35060076
47. Richardson SJ (2007) Cell and molecular biology of transthyretin and thyroid hormones. Int Rev Cytol 258:137-193. doi: 10.1016/ S0074-7696(07)58003-4
48. Kassem NA, Deane R, Segal MB et al (2006) Role of transthyretin in thyroxine transfer from cerebrospinal fluid to brain and choroid plexus. Am J Physiol Regul Integr Comp Physiol 291:R1310-R1315. doi: 10.1152/ ajpregu.00789.2005
49. Palha JA, Nissanov J, Fernandes R et al (2002) Thyroid hormone distribution in the mouse brain: The role of transthyretin. Neuroscience 113:837-847. doi: 10.1016/S0306-4522(02)00228-2
50. Albrecht S, Bayer TA, Kraus JA et al (1995) Transthyretin expression in medulloblastomas and medulloblastoma cell lines. Neuropathol Appl Neurobiol 21:399-409. doi: 10.1111/j.1365-2990.1995.tb01077.x
51. Kunishio K, Shiraishi T, Mishima N et al (1991) Immunohistochemical study for choroid plexus papillomas and ependymomas. Neurol Med Chir (Tokyo) 31:859-866. doi: 10.2176/nmc.31.859
52. Zhang Z, Bast RC Jr, Yu Y et al (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890. doi: 10.1158/0008-5472.CAN-04-0746
53. Fevre-Montange M, Hasselblatt M, Figarella-Branger D et al (2006) Prognosis and histopathologic features in papillary tumors of the pineal region: A retrospective multicenter study of 31 cases. J Neuropathol Exp Neurol 65:1004-1011